Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 175

1.

Safety and immunogenicity of LC16m8, an attenuated smallpox vaccine in vaccinia-naive adults.

Kennedy JS, Gurwith M, Dekker CL, Frey SE, Edwards KM, Kenner J, Lock M, Empig C, Morikawa S, Saijo M, Yokote H, Karem K, Damon I, Perlroth M, Greenberg RN.

J Infect Dis. 2011 Nov;204(9):1395-402. doi: 10.1093/infdis/jir527. Epub 2011 Sep 15.

2.

Recent advances in the study of live attenuated cell-cultured smallpox vaccine LC16m8.

Eto A, Saito T, Yokote H, Kurane I, Kanatani Y.

Vaccine. 2015 Nov 9;33(45):6106-11. doi: 10.1016/j.vaccine.2015.07.111. Epub 2015 Aug 28. Review.

PMID:
26319072
3.

Clinical and immunological response to attenuated tissue-cultured smallpox vaccine LC16m8.

Saito T, Fujii T, Kanatani Y, Saijo M, Morikawa S, Yokote H, Takeuchi T, Kuwabara N.

JAMA. 2009 Mar 11;301(10):1025-33. doi: 10.1001/jama.2009.289.

PMID:
19278946
4.

Freeze-dried live attenuated smallpox vaccine prepared in cell culture "LC16-KAKETSUKEN": Post-marketing surveillance study on safety and efficacy compliant with Good Clinical Practice.

Nishiyama Y, Fujii T, Kanatani Y, Shinmura Y, Yokote H, Hashizume S.

Vaccine. 2015 Nov 9;33(45):6120-7. doi: 10.1016/j.vaccine.2015.09.067. Epub 2015 Oct 9.

5.

Comparative evaluation of the immune responses and protection engendered by LC16m8 and Dryvax smallpox vaccines in a mouse model.

Meseda CA, Mayer AE, Kumar A, Garcia AD, Campbell J, Listrani P, Manischewitz J, King LR, Golding H, Merchlinsky M, Weir JP.

Clin Vaccine Immunol. 2009 Sep;16(9):1261-71. doi: 10.1128/CVI.00040-09. Epub 2009 Jul 15.

6.

Safety and immunogenicity of IMVAMUNEĀ® smallpox vaccine using different strategies for a post event scenario.

Frey SE, Winokur PL, Salata RA, El-Kamary SS, Turley CB, Walter EB Jr, Hay CM, Newman FK, Hill HR, Zhang Y, Chaplin P, Tary-Lehmann M, Belshe RB.

Vaccine. 2013 Jun 24;31(29):3025-33. doi: 10.1016/j.vaccine.2013.04.050. Epub 2013 May 9.

7.

Vaccinia virus strain LC16m8 defective in the B5R gene keeps strong protection comparable to its parental strain Lister in immunodeficient mice.

Yokote H, Shinmura Y, Kanehara T, Maruno S, Kuranaga M, Matsui H, Hashizume S.

Vaccine. 2015 Nov 9;33(45):6112-9. doi: 10.1016/j.vaccine.2015.07.076. Epub 2015 Aug 1.

8.

Analysis of variola and vaccinia virus neutralization assays for smallpox vaccines.

Hughes CM, Newman FK, Davidson WB, Olson VA, Smith SK, Holman RC, Yan L, Frey SE, Belshe RB, Karem KL, Damon IK.

Clin Vaccine Immunol. 2012 Jul;19(7):1116-8. doi: 10.1128/CVI.00056-12. Epub 2012 May 16.

9.

LC16m8, a highly attenuated vaccinia virus vaccine lacking expression of the membrane protein B5R, protects monkeys from monkeypox.

Saijo M, Ami Y, Suzaki Y, Nagata N, Iwata N, Hasegawa H, Ogata M, Fukushi S, Mizutani T, Sata T, Kurata T, Kurane I, Morikawa S.

J Virol. 2006 Jun;80(11):5179-88.

10.

Enhanced immunogenicity and protective effect conferred by vaccination with combinations of modified vaccinia virus Ankara and licensed smallpox vaccine Dryvax in a mouse model.

Meseda CA, Garcia AD, Kumar A, Mayer AE, Manischewitz J, King LR, Golding H, Merchlinsky M, Weir JP.

Virology. 2005 Sep 1;339(2):164-75.

11.

Rapid protection in a monkeypox model by a single injection of a replication-deficient vaccinia virus.

Earl PL, Americo JL, Wyatt LS, Espenshade O, Bassler J, Gong K, Lin S, Peters E, Rhodes L Jr, Spano YE, Silvera PM, Moss B.

Proc Natl Acad Sci U S A. 2008 Aug 5;105(31):10889-94. doi: 10.1073/pnas.0804985105. Epub 2008 Aug 4.

12.

An attenuated LC16m8 smallpox vaccine: analysis of full-genome sequence and induction of immune protection.

Morikawa S, Sakiyama T, Hasegawa H, Saijo M, Maeda A, Kurane I, Maeno G, Kimura J, Hirama C, Yoshida T, Asahi-Ozaki Y, Sata T, Kurata T, Kojima A.

J Virol. 2005 Sep;79(18):11873-91.

13.

Correlations between vaccinia-specific immune responses within a cohort of armed forces members.

Umlauf BJ, Ovsyannikova IG, Haralambieva IH, Kennedy RB, Vierkant RA, Pankratz VS, Jacobson RM, Poland GA.

Viral Immunol. 2011 Oct;24(5):415-20. doi: 10.1089/vim.2011.0029. Epub 2011 Sep 29.

14.

Serological responses in humans to the smallpox vaccine LC16m8.

Johnson BF, Kanatani Y, Fujii T, Saito T, Yokote H, Smith GL.

J Gen Virol. 2011 Oct;92(Pt 10):2405-10. doi: 10.1099/vir.0.034207-0. Epub 2011 Jun 29.

15.

Smallpox vaccine safety is dependent on T cells and not B cells.

Gordon SN, Cecchinato V, Andresen V, Heraud JM, Hryniewicz A, Parks RW, Venzon D, Chung HK, Karpova T, McNally J, Silvera P, Reimann KA, Matsui H, Kanehara T, Shinmura Y, Yokote H, Franchini G.

J Infect Dis. 2011 Apr 15;203(8):1043-53. doi: 10.1093/infdis/jiq162.

16.

Comparison of the safety and immunogenicity of ACAM1000, ACAM2000 and Dryvax in healthy vaccinia-naive adults.

Frey SE, Newman FK, Kennedy JS, Ennis F, Abate G, Hoft DF, Monath TP.

Vaccine. 2009 Mar 4;27(10):1637-44. doi: 10.1016/j.vaccine.2008.11.079. Epub 2008 Dec 9.

PMID:
19071184
17.

Vaccination of BALB/c mice with Escherichia coli-expressed vaccinia virus proteins A27L, B5R, and D8L protects mice from lethal vaccinia virus challenge.

Berhanu A, Wilson RL, Kirkwood-Watts DL, King DS, Warren TK, Lund SA, Brown LL, Krupkin AK, Vandermay E, Weimers W, Honeychurch KM, Grosenbach DW, Jones KF, Hruby DE.

J Virol. 2008 Apr;82(7):3517-29. doi: 10.1128/JVI.01854-07. Epub 2008 Jan 16.

18.

LC16m8: an attenuated smallpox vaccine.

Kenner J, Cameron F, Empig C, Jobes DV, Gurwith M.

Vaccine. 2006 Nov 17;24(47-48):7009-22. Epub 2006 Apr 21. Review.

PMID:
17052815
19.

Development of smallpox vaccine candidates with integrated interleukin-15 that demonstrate superior immunogenicity, efficacy, and safety in mice.

Perera LP, Waldmann TA, Mosca JD, Baldwin N, Berzofsky JA, Oh SK.

J Virol. 2007 Aug;81(16):8774-83. Epub 2007 Jun 6.

20.

Highly attenuated smallpox vaccine protects rabbits and mice against pathogenic orthopoxvirus challenge.

Empig C, Kenner JR, Perret-Gentil M, Youree BE, Bell E, Chen A, Gurwith M, Higgins K, Lock M, Rice AD, Schriewer J, Sinangil F, White E, Buller RM, Dermody TS, Isaacs SN, Moyer RW.

Vaccine. 2006 Apr 24;24(17):3686-94.

PMID:
16430997

Supplemental Content

Support Center